Brief: Aptevo Announces Monotherapy Patient Got Transplant In APVO436 Expansion Trial
29/03/2022 13:35
March 29 (Reuters) - Aptevo Therapeutics Inc APVO.O :
* APTEVO THERAPEUTICS ANNOUNCES MONOTHERAPY PATIENT RECEIVED
A
TRANSPLANT IN APVO436 EXPANSION TRIAL FOR THE TREATMENT OF ACUTE
MYELOID LEUKEMIA
* APTEVO THERAPEUTICS INC - PATIENTS IN BOTH MONOTHERAPY AND
COMBINATION ARMS IN MULTI-COHORT TRIAL HAVE ACHIEVED TRANSPLANT
ELIGIBLE STATUS
Further company coverage: APVO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aptevo Therapeutics
See all newsBrief: Aptevo Therapeutics - Enters Amendment No. 6 To Rights Agreement On October 23, 2026 - SEC Filing
U.S. STOCKS ON THE MOVE-Principal Financial Group, NetApp
U.S. STOCKS ON THE MOVE-Genesco, Fervo Energy, Tyson Foods
Aptevo Therapeutics reports early data for blood cancer therapy; shares fall
Aptevo Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary